3) Gilead Sciences ( GILD)
Even after an undisturbed rise in Gilead, shares broke out from $45, closing recently at $48.94. The implied volatility ranges from 27% – 30.7%. The company provided a clinical trial update for its ION-1 study. The study evaluates taking two drugs concurrently to treat hepatitis C. A safety board review concluded that the study should continue without any modification.
If the treatment is approved, the drug could generate sales of $6 billion or more.
Written by Chris Lau